Lay Guat Ng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lay Guat Ng has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Edwin Jonathan Aslim
Department of Urology, Singapore General Hospital, Singapore
4 shared publications - Angie Beng Guek See
Department of Urology, Singapore General Hospital, Singapore 169608, Singapore
1 shared publication - Aye Aye Thike
Department of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore
1 shared publication - Balamurali B. T.
Science, Mathematics and Technology, Singapore University of Technology and Design, Singapore 487372, Singapore
1 shared publication - Bin Tean Teh
Cancer and Stem Cell Biology Programme, Duke-NUS Medical School, Singapore 169857, Singapore
1 shared publication - Caretha L. Creasy
Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania
1 shared publication
Latest Publications
- Open Access
- 10 November 2025
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
- Vol. 40 (1) , 55-67
Intravenous immunoglobulin and mammalian target of rapamycin inhibitors for treatment of BK virus infections in kidney transplantation: a systematic review
Khi Yung Fong, Terence Kee, Sobhana Thangaraju, Quan Yao Ho, Ian Tatt Liew, Carolyn Tien, Edwin Jonathan Aslim, Lay Guat Ng, Ee Jean Lim, Valerie Huei Li Gan. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0038
- 10 November 2025
- Published by The Korean Society for Transplantation in Clinical Transplantation and Research
- Vol. 40 (1) , 55-67
Open AccessIntravenous immunoglobulin and mammalian target of rapamycin inhibitors for treatment of BK virus infections in kidney transplantation: a systematic review
Khi Yung Fong, Terence Kee, Sobhana Thangaraju, Quan Yao Ho, Ian Tatt Liew, Carolyn Tien, Edwin Jonathan Aslim, Lay Guat Ng, Ee Jean Lim, Valerie Huei Li Gan. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0038
- Open Access
- 14 February 2025
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 6 (1) , 17
Professor Foo Keong Tatt
Professor Foo Keong Tatt is widely celebrated as the “Father of Urology” in Singapore
- 14 February 2025
- Published by MDPI AG in Société Internationale d’Urologie Journal
- Vol. 6 (1) , 17
Open AccessProfessor Foo Keong Tatt
Professor Foo Keong Tatt is widely celebrated as the “Father of Urology” in Singapore
- Open Access
- 10 October 2024
- Published by Elsevier in Continence
- Vol. 12
The clinical application of a novel minimally invasive non-surgical treatment for stress urinary incontinence
- 10 October 2024
- Published by Elsevier in Continence
- Vol. 12
Open AccessThe clinical application of a novel minimally invasive non-surgical treatment for stress urinary incontinence
- 11 July 2022
- Published by Elsevier in European Urology Focus
- Vol. 9 (1) , 209-215
Development and Validation of a Deep Learning System for Sound-based Prediction of Urinary Flow
- 11 July 2022
- Published by Elsevier in European Urology Focus
- Vol. 9 (1) , 209-215
Development and Validation of a Deep Learning System for Sound-based Prediction of Urinary Flow
- 29 June 2019
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 14 (3) , 139-143
The Role of Estrogen Status in the Causation of Female Lower Urinary Tract and Pelvic Floor Dysfunction
- 29 June 2019
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 14 (3) , 139-143
The Role of Estrogen Status in the Causation of Female Lower Urinary Tract and Pelvic Floor Dysfunction
- Open Access
- 1 March 2019
- Published by Elsevier in Urology Case Reports
- Vol. 23, 106-107
'Pop goes the whistle' - Noisy micturition as the main presentation of pneumaturia
- 1 March 2019
- Published by Elsevier in Urology Case Reports
- Vol. 23, 106-107
Open Access'Pop goes the whistle' - Noisy micturition as the main presentation of pneumaturia
- Top Cited Papers
- 22 February 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (378)
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2
Trithorax-like group complex containing KDM6A acts antagonistically to Polycomb-repressive complex 2 (PRC2) containing EZH2 in maintaining the dynamics of the repression and activation of gene expression through H3K27 methylation. In urothelial bladder carcinoma, KDM6A (a H3K27 demethylase) is frequently mutated, but its functional consequences and therapeutic targetability remain unknown. About 70% of KDM6A mutations resulted in a total loss of expression and a consequent loss of demethylase function in this cancer type. Further transcriptome analysis found multiple deregulated pathways, especially PRC2/EZH2, in KDM6A-mutated urothelial bladder carcinoma. Chromatin immunoprecipitation sequencing analysis revealed enrichment of H3K27me3 at specific loci in KDM6A-null cells, including PRC2/EZH2 and their downstream targets. Consequently, we targeted EZH2 (an H3K27 methylase) and demonstrated that KDM6A-null urothelial bladder carcinoma cell lines were sensitive to EZH2 inhibition. Loss- and gain-of-function assays confirmed that cells with loss of KDM6A are vulnerable to EZH2. IGFBP3, a direct KDM6A/EZH2/H3K27me3 target, was up-regulated by EZH2 inhibition and contributed to the observed EZH2-dependent growth suppression in KDM6A-null cell lines. EZH2 inhibition delayed tumor onset in KDM6A-null cells and caused regression of KDM6A-null bladder tumors in both patient-derived and cell line xenograft models. In summary, our study demonstrates that inactivating mutations of KDM6A, which are common in urothelial bladder carcinoma, are potentially targetable by inhibiting EZH2.
- 22 February 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (378)
Top Cited PapersLoss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2
Trithorax-like group complex containing KDM6A acts antagonistically to Polycomb-repressive complex 2 (PRC2) containing EZH2 in maintaining the dynamics of the repression and activation of gene expression through H3K27 methylation. In urothelial bladder carcinoma, KDM6A (a H3K27 demethylase) is frequently mutated, but its functional consequences and therapeutic targetability remain unknown. About 70% of KDM6A mutations resulted in a total loss of expression and a consequent loss of demethylase function in this cancer type. Further transcriptome analysis found multiple deregulated pathways, especially PRC2/EZH2, in KDM6A-mutated urothelial bladder carcinoma. Chromatin immunoprecipitation sequencing analysis revealed enrichment of H3K27me3 at specific loci in KDM6A-null cells, including PRC2/EZH2 and their downstream targets. Consequently, we targeted EZH2 (an H3K27 methylase) and demonstrated that KDM6A-null urothelial bladder carcinoma cell lines were sensitive to EZH2 inhibition. Loss- and gain-of-function assays confirmed that cells with loss of KDM6A are vulnerable to EZH2. IGFBP3, a direct KDM6A/EZH2/H3K27me3 target, was up-regulated by EZH2 inhibition and contributed to the observed EZH2-dependent growth suppression in KDM6A-null cell lines. EZH2 inhibition delayed tumor onset in KDM6A-null cells and caused regression of KDM6A-null bladder tumors in both patient-derived and cell line xenograft models. In summary, our study demonstrates that inactivating mutations of KDM6A, which are common in urothelial bladder carcinoma, are potentially targetable by inhibiting EZH2.